PHVS Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pharvaris N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.17 |
| 52 Week High | US$33.00 |
| 52 Week Low | US$15.37 |
| Beta | -3.15 |
| 11 Month Change | 11.31% |
| 3 Month Change | 34.55% |
| 1 Year Change | 36.91% |
| 33 Year Change | 64.28% |
| 5 Year Change | n/a |
| Change since IPO | -16.67% |
Recent News & Updates
Recent updates
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Aug 16
Pharvaris: Digging Deep For Sufficient Market Size
Jan 17We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Oct 09Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
May 13Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
Jan 11We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Sep 26Pharvaris GAAP EPS of -€0.38
Sep 12Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Aug 22We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Jun 08Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Dec 21We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Aug 25Pharvaris reports Q1 results
May 26Shareholder Returns
| PHVS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 17.8% | 4.2% | 2.0% |
| 1Y | 36.9% | 13.7% | 32.4% |
Return vs Industry: PHVS exceeded the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: PHVS exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| PHVS volatility | |
|---|---|
| PHVS Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHVS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 92 | Berndt Axel Modig | pharvaris.com |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Pharvaris N.V. Fundamentals Summary
| PHVS fundamental statistics | |
|---|---|
| Market cap | US$1.28b |
| Earnings (TTM) | -US$138.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.5x
P/E RatioIs PHVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHVS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €132.21m |
| Earnings | -€132.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHVS perform over the long term?
See historical performance and comparison